DE69821252D1 - Verwendung von einem angiotensin ii antagonist zur herstellung eines arzneistoffs zur steigerung der überlebung von nieren transplantieren patienten - Google Patents

Verwendung von einem angiotensin ii antagonist zur herstellung eines arzneistoffs zur steigerung der überlebung von nieren transplantieren patienten

Info

Publication number
DE69821252D1
DE69821252D1 DE69821252T DE69821252T DE69821252D1 DE 69821252 D1 DE69821252 D1 DE 69821252D1 DE 69821252 T DE69821252 T DE 69821252T DE 69821252 T DE69821252 T DE 69821252T DE 69821252 D1 DE69821252 D1 DE 69821252D1
Authority
DE
Germany
Prior art keywords
survival
angiotensin
antagonist
kidney
producing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69821252T
Other languages
English (en)
Other versions
DE69821252T2 (de
Inventor
Giuseppe Remuzzi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Italia SpA
Original Assignee
Merck Sharp and Dohme Italia SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Italia SpA filed Critical Merck Sharp and Dohme Italia SpA
Application granted granted Critical
Publication of DE69821252D1 publication Critical patent/DE69821252D1/de
Publication of DE69821252T2 publication Critical patent/DE69821252T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE1998621252 1997-09-30 1998-09-30 Verwendung eines Angiotensin-II Antagonisten zur Herstellung von Arzneistoffen zur Erhöhung der Überlebensrate von Nierentransplantationspatienten Expired - Lifetime DE69821252T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITRM970586 1997-09-30
IT97RM000586A IT1295405B1 (it) 1997-09-30 1997-09-30 Uso di un antagonista recettoriale di angiotensina ii per la preparazione di farmaci per aumentare il tasso di sopravvivenza di
PCT/IT1998/000259 WO1999016437A1 (en) 1997-09-30 1998-09-30 Use of an angiotensin ii receptor antagonist for the preparation of drugs to increase the survival rate of renal transplant patients

Publications (2)

Publication Number Publication Date
DE69821252D1 true DE69821252D1 (de) 2004-02-26
DE69821252T2 DE69821252T2 (de) 2004-11-18

Family

ID=11405271

Family Applications (1)

Application Number Title Priority Date Filing Date
DE1998621252 Expired - Lifetime DE69821252T2 (de) 1997-09-30 1998-09-30 Verwendung eines Angiotensin-II Antagonisten zur Herstellung von Arzneistoffen zur Erhöhung der Überlebensrate von Nierentransplantationspatienten

Country Status (12)

Country Link
US (1) US6576652B2 (de)
EP (1) EP1019048B1 (de)
JP (1) JP2001517698A (de)
AT (1) ATE258051T1 (de)
AU (1) AU754852B2 (de)
CA (1) CA2303217C (de)
DE (1) DE69821252T2 (de)
DK (1) DK1019048T3 (de)
ES (1) ES2213296T3 (de)
IT (1) IT1295405B1 (de)
PT (1) PT1019048E (de)
WO (1) WO1999016437A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
BR0102252B1 (pt) 2001-04-10 2013-10-22 Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso
DE60304175T2 (de) 2002-04-29 2007-03-15 Teva Pharmaceutical Industries Ltd. Verfahren zur herstellung von losartan und losartan-kaliumsalz
WO2005097109A1 (en) * 2004-04-01 2005-10-20 Daniel Batlle Methods for achieving a protective ace2 expression level
WO2005110386A2 (en) * 2004-04-13 2005-11-24 Wisconsin Alumni Research Foundation Method of decreasing inflammation in kidney transplantation using angiotensin receptor blockers
US7531560B2 (en) * 2004-11-10 2009-05-12 Boehringer Ingelheim Pharmaceuticals, Inc. Anti-cytokine heterocyclic compounds
ES2753874T3 (es) * 2009-04-28 2020-04-14 Daiichi Sankyo Co Ltd Cristales de solvato novedosos
AU2013345894B2 (en) * 2012-11-14 2017-05-25 Teijin Limited Pyridine derivative
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
AU2019246406A1 (en) * 2018-03-29 2020-10-15 Bruno Reichart Compositions for prolonging the survival after orthopic and heteropic xenogeneic heart, kidney, lung or liver transplantations

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH528514A (de) 1969-05-22 1972-09-30 Bayer Ag Verfahren zur Herstellung von Acylimidazolen
JPS54148788A (en) 1978-05-15 1979-11-21 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative and its preparation
JPS55313A (en) 1978-06-13 1980-01-05 Kissei Pharmaceut Co Ltd Imidazole derivative
DK531479A (da) 1979-01-19 1980-07-20 Pfizer Fremgangsmaade til fremstilling af imidazolderivater og salte deraf
JPS5671073A (en) 1979-11-12 1981-06-13 Takeda Chem Ind Ltd Imidazole derivative
JPS5671074A (en) 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
DE3106150A1 (de) 1981-02-13 1982-09-16 Schering Ag, 1000 Berlin Und 4619 Bergkamen "verfahren zur herstellung von imidazolessigsaeurederivaten"
JPS58157768A (ja) 1982-03-16 1983-09-19 Takeda Chem Ind Ltd ４−クロロ−２−フエニルイミダゾ−ル−５−酢酸誘導体
PT78388B (en) 1983-04-12 1986-09-15 Smithkline Beckman Corp Dopamine-beta-hydroxylase inhibitors
FI833794A0 (fi) 1983-10-18 1983-10-18 Farmos Oy Substituerade 2-merkapto-imidazoler
US5138069A (en) 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
US5064825A (en) * 1989-06-01 1991-11-12 Merck & Co., Inc. Angiotensin ii antagonists
EP0505098A1 (de) * 1991-03-19 1992-09-23 Merck & Co. Inc. Imidazolderivate mit funktionelle Säuregruppen als Angiotensin-II-Antagoniste
US5492904A (en) * 1991-05-15 1996-02-20 E. I. Du Pont De Nemours And Company Composition of angiotensin-II receptor antagonists and calcium channel blockers
US5130439A (en) 1991-11-18 1992-07-14 Lo Young S Tetrazolylphenylboronic acid intermediates for the synthesis of AII receptor antagonists
DE69233208T2 (de) 1991-11-18 2004-07-08 E.I. Du Pont De Nemours And Co., Wilmington Tetrazolylphenylborsäureintermediate zur synthese von aii rezeptor antagonisten
US5219856A (en) * 1992-04-06 1993-06-15 E. I. Du Pont De Nemours And Company Angiotensin-II receptor blocking, heterocycle substituted imidazoles
US5310929A (en) * 1992-08-06 1994-05-10 E. I. Du Pont De Nemours And Company Prodrugs of imidazole carboxylic acids as angiotensin II receptor antagonists
US5395844A (en) * 1993-06-10 1995-03-07 The Du Pont Merck Pharmaceutical Company Imidazole 5-position substituted angiotensin II antagonists
BR9611007A (pt) * 1995-10-06 1999-07-13 Novartis Ag Antagonistas do receptor at1 para prevenir e tratar a deficiência renal pós-isquêmica e para a proteção de rins isquêmicos
CA2238975A1 (en) * 1995-12-12 1997-06-19 Merck & Co., Inc. New use for losartan

Also Published As

Publication number Publication date
US20020115702A1 (en) 2002-08-22
PT1019048E (pt) 2004-05-31
AU754852B2 (en) 2002-11-28
DE69821252T2 (de) 2004-11-18
CA2303217A1 (en) 1999-04-08
EP1019048A1 (de) 2000-07-19
JP2001517698A (ja) 2001-10-09
ITRM970586A1 (it) 1999-03-30
DK1019048T3 (da) 2004-05-03
ATE258051T1 (de) 2004-02-15
WO1999016437A1 (en) 1999-04-08
IT1295405B1 (it) 1999-05-12
CA2303217C (en) 2005-08-09
EP1019048B1 (de) 2004-01-21
AU9366698A (en) 1999-04-23
ES2213296T3 (es) 2004-08-16
US6576652B2 (en) 2003-06-10

Similar Documents

Publication Publication Date Title
KR960704884A (ko) 항종양제 또는 항바이러스제로서의 디스타마이신 A 동족체 (Distamycin A analogues as antitumour or antiviral agents)
KR910007918A (ko) 치환된5-[(테트라졸릴)알케닐]이미다졸
WO2005113537B1 (en) Urea antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
DE69821252D1 (de) Verwendung von einem angiotensin ii antagonist zur herstellung eines arzneistoffs zur steigerung der überlebung von nieren transplantieren patienten
PT73879B (de) 1-carboxyalkanoylindolin-2-carbonsauren verfahren zu ihrer herstellung und pharmazeutische praeparate enthaltend diese verbindungen sowie ihre therapeutische verwendung
CA2643005A1 (en) Imidazole-5-carboxylic acid derivatives,the preparation method therefor and the uses thereof
MX2010001368A (es) Forma cristalina de la sal diclorhidrato de ((1s)-1-(((2s)-2-(5-(4 ´-(2-((2s)-1-((2s)-2-((metoxicarbonil) amino)-3-metilbutanoil)-2-p irrolidinil)-1h-imidazol-5-il)-4-bifenilil)-1h-imidazol-2-il)-1-p irrolidinil) carbonil)-2-metilpropil)carbamato de
EA200501332A1 (ru) Производные пиримидин-4-она и их применение в качестве модуляторов киназы p38
WO1992000067A3 (en) Treatment of chronic renal failure with imidazole angiotensin-ii receptor antagonists
WO2000067735A3 (en) USE OF SELECTIVE ANTAGONISTS OF THE α1b-ADRENERGIC RECEPTOR FOR IMPROVEMENT OF SEXUAL DYSFUNCTION
JP2006501201A5 (de)
EP0096569A3 (de) Triazole mit pilztötender Wirkung
US20230372372A1 (en) Combination therapies using caspase-1 dependent anticancer agents and pge2 antagonists
JPH06503335A (ja) 糖尿病性網膜症の治療におけるアンジオテンシン２受容体拮抗剤の使用
IE913992A1 (en) Angiotensin II-receptor-blockers for the treatment of cardiac and of vascular hypertrophy and hyperplasia
BRPI0409959A (pt) uso de derivados de azetidinacarboxamida em terapia
GB2352972A (en) Use of dexmedetomidine for icu sedation
JPH06503337A (ja) 再狭窄の予防におけるアンジオテンシン２受容体拮抗剤の使用
JPH06503322A (ja) 梗塞形成の処置におけるアンジオテンシン２拮抗剤の使用
RU2001105092A (ru) Имидазольные соединения и их применение в качестве ингибиторов аденозиндезаминазы
US20020058686A1 (en) Medicament
JPH06503338A (ja) 認識機能改善用医薬の調製におけるアンジオテンシン２受容体拮抗剤の使用
JPH06503334A (ja) 左心室肥大の治療におけるアンジオテンシン２受容体拮抗剤の使用
US6028091A (en) Medicament
EE05300B1 (et) Akrloldistamtsiini derivaati sisaldav farmatseutiline kompositsioon, derivaadi kasutamine tuumorivastase ravimi valmistamiseks ning kombineeritud ravimpreparaat

Legal Events

Date Code Title Description
8364 No opposition during term of opposition